BackImmunoCellular Therapeutics, Overview

ImmunoCellular Therapeutics, EBIT

EBIT (Earnings Before Interest and Taxes) analysis for IMUC.

Quarterly EBIT

$39.59K
↑ 105.57% YoY

As of Sep 30, 2023

Annual EBIT (TTM)

-$549.25K
↑ 74.49% YoY

Trailing 12 months ending Sep 30, 2023

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Jump to metric
Total RevenueCost of RevenueGross ProfitResearch & DevelopmentSelling, General & AdminOperating IncomeOther Income Expense NetEBITIncome TaxNet IncomeProfit Margin